Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 18/20 | 0.63 |
| ▸ | GHSR | Q92847 | 2/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331814 | 0.94 | IL23R (0.67) | IL23R | |
| SCHEMBL11331799 | 0.94 | IL23R (0.67) | IL23R | |
| SCHEMBL31092855 | 0.93 | IL23R (0.67) | IL23RGHSRNPY2R | |
| SCHEMBL34467247 | 0.93 | IL23R (0.64) | IL23R | |
| SCHEMBL30276231 | 0.92 | IL23R (0.66) | IL23R | |
| SCHEMBL29461984 | 0.92 | NPBWR1 (0.62) | IL23RGHSRNPY2R | |
| SCHEMBL29659700 | 0.92 | IL23R (0.59) | IL23RGHSRNPY2R | |
| SCHEMBL29702300 | 0.92 | IL23R (0.59) | IL23RGHSRNPY2R | |
| SCHEMBL30701867 | 0.91 | IL23R (0.58) | IL23RGHSRNPY2R | |
| SCHEMBL30701871 | 0.91 | IL23R (0.58) | IL23RGHSRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | HAMILTON DOUGLAS A (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2024-03-14 | — | — | US | disclosed |
| EP-4132491-A2 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | Vasomune Therapeutics Inc. (CA) | 2023-02-15 | — | — | EP | disclosed |
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | HAMILTON DOUGLAS A (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | SARS1, ACE2, TMPRSS2 | IL23R 728/4885GHSR 2317/4885NPY2R 3873/4885 |
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | SARS1, ACE2, TMPRSS2 | IL23R 728/4885GHSR 2317/4885NPY2R 3873/4885 |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VEGFA, PGF, FLT4 | IL23R 1841/4885GHSR 1041/4885NPY2R 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.